Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advertisement
Emily MenendezAdvanced Renal Cell Carcinoma | March 17, 2023
Patients with accRCC were assigned to receive either a conventional continuation strategy or a drug-free interval strategy.
Read More
Emily MenendezAdvanced Renal Cell Carcinoma | March 10, 2023
Plasma and urine free glycosaminoglycan profiles—or GAGomes—can potentially be used as metabolic biomarkers for mRCC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 8, 2023
Dr. McKay explains how radiation therapy and modalities fit into the treatment paradigm for RCC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 8, 2023
Dr. McKay summarizes the novel therapies or optimal sequencing patterns that are close to entering the mRCC treatment space.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 8, 2023
Dr. McKay offers an overview of the second-line and later-line therapy options after progression for metastatic RCC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 8, 2023
Dr. McKay highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk mRCC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 8, 2023
Dr. Rana McKay details how advanced or mRCC is currently managed and how the treatment paradigm has evolved since 2018.
Michael B. Atkins, MDASCO GU Symposium 2023 | February 18, 2023
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
Researchers assessed TFS outcomes from HCRN GU16-260, investigating nivolumab and salvage nivolumab plus ipilimumab for aRCC.
Zachary BessetteASCO GU Symposium 2023 | February 17, 2023
Updated OS and efficacy results of second-line treatment in patients with mRCC treated in the BIONIKK trial were presented.
Zachary BessetteASCO GU Symposium 2023 | February 17, 2023
Latinx patients with mRCC demonstrated shorter PFS after nivolumab-plus-ipilimumab treatment at a tertiary care center.
Zachary BessetteASCO GU Symposium 2023 | February 17, 2023
A 24-month analysis highlighted OS, PFS, ORR, and best response to avelumab-plus-axitinib treatment in patients with aRCC.
Tian Zhang, MDASCO GU Symposium 2023 | February 16, 2023
Tian Zhang, MD, describes the current standard-of care treatment approach for metastatic RCC, including second-line therapy.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | February 14, 2023
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.
Emily MenendezAdvanced Renal Cell Carcinoma | February 3, 2023
Pembrolizumab/axitinib is a common first-line mRCC treatment, but its use in later lines of therapy has not been researched.
Emily MenendezAdvanced Renal Cell Carcinoma | January 25, 2023
Researchers performed a cost-effectiveness analysis of sunitinib and 6 immunotherapy-TKI/immunotherapy drug combinations.
Zachary BessetteAdvanced Renal Cell Carcinoma | January 5, 2023
Three of the guideline authors offered additional information on cytoreductive nephrectomy and systemic treatment.
Robert DillardIKCS 2022 | December 18, 2022
A study evaluated how accurately prospectively collected renal mass biopsy can identify DNA mutations in nephrectomy.
Robert DillardIKCS 2022 | December 18, 2022
Gut bacteria play a role in the development of sarcopenia in metastatic renal cell carcinoma.
Robert DillardIKCS 2022 | December 18, 2022
Following AUA guidelines may increase survival in kidney cancer.
Advertisement
Advertisement
Advertisement